Insuman Implantable 400 IU/ml insulin solution for infusion: no new patients should be started due to discontinuation of MiniMed Implantable Pump

Dear Healthcare Professional,

Medtronic, in agreement with the European Medicines Agency and the <National Competent Authority> would like to inform you of the following:

Summary

- **The Medtronic MiniMed Implantable Pump (MIP) to be used with Insuman Implantable 400 IU/ml will go out of production by end of 2020, due to ongoing difficulties in the supply of pump components.**
- **New patients should not have a MIP implanted, even if they qualify for intra-peritoneal insulin administration; possible treatment alternatives should be considered.**
- **Available MIPs should be allocated only to patients previously implanted with a MIP and requiring a pump replacement.**
- **Treatment alternatives should also be discussed with existing patients before their MIP stops working, in view of the complete unavailability of new MIPs in the near future.**
- **Insuman Implantable 400 IU/ml and all MIP accessories and consumables (such as refill kits, catheters of different lengths, sodium hydroxide cleaning solution and special buffer) will continue to be supplied for as long as patients use a MIP.**

Background information

In July 2017, Medtronic informed healthcare professionals and the Regulatory Authorities in France, Netherlands, Sweden and Belgium of the decision to stop the production of the Medtronic MiniMed Implantable Pump (MIP), to be used with Insuman Implantable 400 IU/ml. Discontinuation is planned by end of 2020.

MIPs require highly specialized components. Over time, a growing number of these components came to end-of-life, or their production was stopped by suppliers. This resulted in frequent interruptions to the supply of MIPs, which led Medtronic to decide to discontinue production of the MIP and issue an announcement in July 2017.

Medtronic managed to stabilize several critical component supplies; however, production of the MIP remains subject to supply challenges. Medtronic investigated the establishment of an industry partnership to ensure development of a state-of-the-art alternative implantable insulin pump. While this undertaking will continue, so far it has not been successful.

Medtronic considers that subcutaneous insulin delivery combined with continuous glucose measurement and integrated algorithms for treatment management offers the best combination for most Diabetes Type 1 patients whose diabetes control required implantation with a MIP.

It is acknowledged that subcutaneous insulin administration may not be a suitable alternative for all MIP patients; however, considering the imminent discontinuation of MIP production, Medtronic invites you to timely discuss a replacement therapy with your patients and provide them with the enclosed Dear Patient letter at the earliest convenience, i.e. at their next refill procedure. The Dear Patient letter was reviewed and approved by EMA; please consider using this letter as it is.

During this transition period Medtronic will continue the production of MIP and it may take until end-2020 to fulfil the previous supply commitment of 125 MIP units. As the remaining MIP units may not allow to fulfill all needs during this transition period, they will have to be allocated only to patients previously implanted with a MIP and requiring a pump replacement. MIP should not be implanted in new patients, even if they qualify for intra-peritoneal insulin administration.

Sanofi will continue to produce Insuman Implantable 400 IU/ml for as long as MIPs are used by patients. Medtronic will continue to provide technical support to you and MIP patients as well as to MIP patients who switch to the Medtronic subcutaneous insulin delivery platform.

Sincerely,

Annex I – Patient letter

Dear Patient,

In July 2017, Medtronic announced its decision to stop the production of the Medtronic MiniMed Implantable Pump (MIP). This decision was not taken easily, and it was based on a long period of manufacturing challenges that resulted in frequent interruptions of the supply of MIP pumps to the market. With this letter we like to inform you on the current MIP production and what this could mean to you as patient.

Information on MIP production

In 2017, Medtronic expected to stop production around June 2019. At present, we estimate that production of MIP will continue until end-2020. On one hand this is good news, however, the production quantities are very low and not all patients who need a MIP replacement can receive one immediately.

The reason for the low production yield of MIP pumps is the supply of components. The MIP pump is a very complex device with many components that all must work smooth together to ensure accurate insulin delivery. There are many components, including electronics, pumping mechanisms, tubing, connectors, etc. For the MIP, the outer shell and all internal components are supplied by external manufacturers. The MIP was developed ± 20 years ago and, over time, many of these external manufacturers stopped production of these components and Medtronic had to find other manufacturers able and willing to produce these components. Once found, such components must be produced and extensively tested and approved by Medtronic and by Regulatory Authorities. All this takes a lot of time and results in interruption of the production and supply of MIP pumps. And while in this way Medtronic has been able to resolve several critical component supply issues, new issues keep coming up.

What this could mean to you as Patient

This letter is to inform you that although Medtronic has decided to stop production of MIP by end-2020, Medtronic will continue to supply all accessories and consumables such as the refill kit, catheters of different lengths, the sodium hydroxide cleaning solution and the special buffer, for as long as patients use a MIP. The supply of accessories and consumables is therefore independent of MIP production.

Sanofi have confirmed they will continue to supply Insuman Implantable 400IU/ml insulin (the insulin that is used in MIP pumps) for as long as patients use a MIP. Again, the supply of Insuman Implantable 400IU/ml insulin is therefore independent of MIP production.

In view of the complete unavailability of new MIPs in the near future, this letter is also to inform you that it would be prudent for you and your doctor to start discussing replacement treatment options long before your MIP stops working. In this way you could decide to test whether you can benefit, or not, from other current diabetes treatments.

We understand that switching therapy is a journey that will require significant effort from you and your doctor. Medtronic offers free-of-charge the latest external insulin pump with integrated algorithm for treatment management and the CGM sensors for each MIP patient for two years and is committed to accompany you and your doctor during this transition period.

Sincerely,

DHPC COMMUNICATION PLAN	
Medicinal product(s)/active substance(s)	INSUMAN (insulin human)
Marketing authorisation holder(s)	Sanofi-aventis groupe
Safety concern and purpose of the communication	Discontinuation of the production of the Medtronic MiniMed Implantable Insulin Pump (MIP) that administers Sanofi Insuman Implantable 400IU insulin
DHPC recipients	Diabetologists treating diabetes Type 1 patients with the Medtronic MiniMed Implantable Insulin Pump (MIP) that administers Sanofi Insuman Implantable 400IU insulin
Member States where the DHPC will be distributed	Belgium, France, the Netherlands, Sweden, where Medtronic MiniMed Implantable Insulin Pump (MIP) is used to administer Sanofi Insuman Implantable 400IU insulin.

Timetable	Date
DHPC and communication plan (in English) agreed by CHMP/CMDh	02 June 2020
Submission of translated DHPCs to the national competent authorities for review	22 June 2020
Agreement of translations by national competent authorities	06 July 2020
Dissemination of DHPC	20 July 2020